PL3057959T3 - Inhibitory DNA-PK - Google Patents

Inhibitory DNA-PK

Info

Publication number
PL3057959T3
PL3057959T3 PL14800181T PL14800181T PL3057959T3 PL 3057959 T3 PL3057959 T3 PL 3057959T3 PL 14800181 T PL14800181 T PL 14800181T PL 14800181 T PL14800181 T PL 14800181T PL 3057959 T3 PL3057959 T3 PL 3057959T3
Authority
PL
Poland
Prior art keywords
inhibitors
dna
Prior art date
Application number
PL14800181T
Other languages
English (en)
Polish (pl)
Inventor
Paul S. Charifson
Kevin Michael Cottrell
Hongbo Deng
John P. Duffy
Huai Gao
Simon Giroux
Jeremy Green
Katrina Lee Jackson
Joseph M. Kennedy
David J. Lauffer
Mark Willem Ledeboer
Pan Li
John Patrick Maxwell
Mark A. Morris
Albert Charles Pierce
Nathan D. Waal
Jinwang Xu
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/056,560 external-priority patent/US9376448B2/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL3057959T3 publication Critical patent/PL3057959T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14800181T 2013-10-17 2014-10-17 Inhibitory DNA-PK PL3057959T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/056,560 US9376448B2 (en) 2012-04-24 2013-10-17 DNA-PK inhibitors
EP14800181.1A EP3057959B1 (en) 2013-10-17 2014-10-17 Dna-pk inhibitors
PCT/US2014/061033 WO2015058031A1 (en) 2013-10-17 2014-10-17 Dna-pk inhibitors

Publications (1)

Publication Number Publication Date
PL3057959T3 true PL3057959T3 (pl) 2018-08-31

Family

ID=51932571

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14800181T PL3057959T3 (pl) 2013-10-17 2014-10-17 Inhibitory DNA-PK

Country Status (17)

Country Link
EP (1) EP3057959B1 (show.php)
JP (1) JP6374959B2 (show.php)
CN (1) CN105636958B (show.php)
AU (1) AU2014337208B2 (show.php)
BR (1) BR112016008423B1 (show.php)
CA (1) CA2927392C (show.php)
DK (1) DK3057959T3 (show.php)
ES (1) ES2671354T3 (show.php)
HR (1) HRP20180804T1 (show.php)
HU (1) HUE037516T2 (show.php)
LT (1) LT3057959T (show.php)
PL (1) PL3057959T3 (show.php)
PT (1) PT3057959T (show.php)
RS (1) RS57306B1 (show.php)
SI (1) SI3057959T1 (show.php)
TR (1) TR201807411T4 (show.php)
WO (1) WO2015058031A1 (show.php)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (show.php) 2012-06-13 2015-07-17 Hoffmann La Roche
MA37940B1 (fr) 2012-09-25 2018-09-28 Hoffmann La Roche Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
EP3590939A1 (en) 2014-03-26 2020-01-08 F. Hoffmann-La Roche AG Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
MX2018002217A (es) 2015-09-24 2018-03-23 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de autotaxina (atx).
CA2984585A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
TW201900180A (zh) * 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
HRP20211380T1 (hr) * 2017-05-18 2021-11-26 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
SI3625224T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituirani indolni derivati
AU2018368790A1 (en) 2017-11-20 2020-06-25 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
KR20200110687A (ko) 2018-01-17 2020-09-24 버텍스 파마슈티칼스 인코포레이티드 유전체 편집 효율을 증가시키기 위한 퀴녹살리논 화합물, 조성물, 방법 및 키트
JP7466448B2 (ja) 2018-01-17 2024-04-12 バーテックス ファーマシューティカルズ インコーポレイテッド Dna-pk阻害剤
EP3768267B1 (en) 2018-03-20 2025-05-14 Icahn School of Medicine at Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
AU2019418800A1 (en) * 2018-12-31 2021-07-01 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN112300126A (zh) * 2019-07-31 2021-02-02 山东轩竹医药科技有限公司 杂环类dna-pk抑制剂
CN112574179B (zh) * 2019-09-29 2022-05-10 山东轩竹医药科技有限公司 Dna-pk抑制剂
CN112574211B (zh) * 2019-09-29 2022-06-14 山东轩竹医药科技有限公司 杂环类激酶抑制剂
KR102786205B1 (ko) * 2019-12-31 2025-03-31 청두 바이위 파머수티컬 씨오., 엘티디 퓨린 유도체 및 의학에서의 그의 용도
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179912B2 (en) * 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
CN103739595A (zh) * 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EA201201274A1 (ru) * 2010-03-10 2013-04-30 Инджениум Фармасьютиклз Гмбх Ингибиторы протеинкиназ
IN2014KN02601A (show.php) * 2012-04-24 2015-05-08 Vertex Pharma

Also Published As

Publication number Publication date
EP3057959A1 (en) 2016-08-24
ES2671354T3 (es) 2018-06-06
AU2014337208B2 (en) 2018-05-24
HRP20180804T1 (hr) 2018-08-10
HUE037516T2 (hu) 2018-09-28
CA2927392C (en) 2021-11-09
LT3057959T (lt) 2018-06-11
BR112016008423A2 (show.php) 2017-08-01
SI3057959T1 (en) 2018-07-31
JP6374959B2 (ja) 2018-08-15
TR201807411T4 (tr) 2018-06-21
CN105636958B (zh) 2018-01-05
RS57306B1 (sr) 2018-08-31
CN105636958A (zh) 2016-06-01
DK3057959T3 (en) 2018-06-06
PT3057959T (pt) 2018-06-04
BR112016008423B1 (pt) 2022-02-22
CA2927392A1 (en) 2015-04-23
JP2016533366A (ja) 2016-10-27
WO2015058031A1 (en) 2015-04-23
EP3057959B1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
HUE037516T2 (hu) DNS-PK inhibitorok
SG11201507203RA (en) Dna-pk inhibitors
ZA201407554B (en) Dna-pk inhibitors
SG11201507541PA (en) CDC7 Inhibitors
PL2964616T3 (pl) Inhibitory neprylizyny
ZA201506156B (en) Novel inhibitors
GB201314578D0 (en) Bicyclic inhibitors
IL245245A0 (en) New dgat2 inhibitors
IL245737A0 (en) Glucosylceramide synthase inhibitors
IL246230A0 (en) Amines thf quinazoline as pde1 inhibitors
GB201307155D0 (en) Kinase inhibitors
GB201305503D0 (en) Inhibitor